| |  Online-Ressource |
|---|
| Verfasst von: | Magios, Nikolaus [VerfasserIn]  |
|---|
| | Bozorgmehr, Farastuk [VerfasserIn] |
|---|
| | Volckmar, Anna-Lena [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Herth, Felix [VerfasserIn] |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | Eichhorn, Florian [VerfasserIn] |
|---|
| | Meister, Michael [VerfasserIn] |
|---|
| | Muley, Thomas [VerfasserIn] |
|---|
| | El-Shafie, Rami [VerfasserIn] |
|---|
| | Fischer, Jürgen [VerfasserIn] |
|---|
| | Faehling, Martin [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Bischoff, Helge [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| Titel: | Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer |
|---|
| Verf.angabe: | Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | March 24, 2021 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 12.06.2021 |
|---|
| Titel Quelle: | Enthalten in: Therapeutic advances in medical oncology |
|---|
| Ort Quelle: | Thousand Oaks, Calif. : Sage, 2009 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 13(2021) vom: Jan., Artikel-ID 1758835921996509, Seite 1-13 |
|---|
| ISSN Quelle: | 1758-8359 |
|---|
| Abstract: | Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.Methods:EGFR+ NSCLC patients treated with first/second-generation (1G/2G) TKI at our institution with a last follow-up after osimertinib approval (February 2016), were analyzed retrospectively, and the results compared with published data under osimertinib.Results:A total of 207 patients received erlotinib (37%), gefitinib (16%) or afatinib (47%). The median age was 66?years, with a predominance of female (70%), never/light-smokers (69%). T790M testing was performed in 174/202 progressive cases (86%), positive in 93/174 (53%), and followed by osimertinib in 87/93 (94%). Among the 135 deceased patients, 94 (70%) received subsequent systemic treatment (43% chemotherapy, 39% osimertinib), while 30% died without, either before (4%) or after progression, due to rapid clinical deterioration (22%), patient refusal of further therapy (2%), or severe competing illness (2%). Lack of subsequent treatment was significantly (4.5x, p? |
|---|
| DOI: | doi:10.1177/1758835921996509 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1177/1758835921996509 |
|---|
| | DOI: https://doi.org/10.1177/1758835921996509 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | EGFR T790M mutation |
|---|
| | EGFR+ NSCLC |
|---|
| | overall survival |
|---|
| | rebiopsy |
|---|
| | second line |
|---|
| | tyrosine kinase inhibitor |
|---|
| K10plus-PPN: | 1760352888 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer / Magios, Nikolaus [VerfasserIn]; March 24, 2021 (Online-Ressource)
